Thorne HealthTech — Investor Presentation (December 2021)
34 slides from Thorne HealthTech's investor presentation, Dec 6, 2021
Slide 1: Thorne HealthTech Investor Presentation December 2021
Thorne HealthTech Investor Presentation December 2021 Exhibit 99.1
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been made available to you with the consent of Thorne for informational purposes only and for you to familiarize yourself with its business. This presentation is strictly confidential and may not be reproduced or redistributed in whole or in part, nor may
Slide 3: Today's Presenters
Thorne HealthTech Today’s Presenters Paul JacobsonCo-founder, Chief Executive Officer11 years @ Thorne HealthTech 4
Slide 4: Introducing Thorne HealthTech
Introducing Thorne HealthTech 5
Slide 5: Our Mission
To bring the scientific rigor of biotech and pharma to the prevention space and extend the length of time people can live healthier lives. Proprietary & Confidential Our Mission Thorne HealthTech
Slide 6: Thorne HealthTech Is Personalized, Scientific Wellness
Thorne HealthTech Is Personalized, Scientific Wellness Our Opportunity Thorne HealthTech Clinically tested, high quality nutritional supplements Identifying compounds for new indications Education and testing to help consumers understand their needs Medical professionals and athletes trust and recom
Slide 7: Our Vertically Integrated Platform
Our Vertically Integrated Platform Thorne Supplements Premium, high-quality supplements Rigorous R&D process Comprehensive testing for quality control Powerful brand for health professionals and consumers Thorne Health Tests Health tests with comprehensive, personalized results Extensive portfolio i
Slide 8: Thorne Has Created a Trusted, Luxury Brand
Premium Pricing Vertical Integration Product Excellence Health as the New Wealth Thorne Has Created a Trusted, Luxury Brand Personalization Trend Setters 11 U.S. Olympic Teams Our Ingredients Supported by Clinical Data or Medical Research 100+ Professional Sports Teams Mayo Clinic Collaborator 45k H
Slide 9: Redefining Consumer Health and Wellness
Redefining Consumer Health and Wellness Convenient, test collections start customer health journey. Includes actionable health plan. 10 Health Tests 4 sample domains (blood, saliva, urine, stool) Premium nutritional solutions to optimize an individual’s unique needs. 300+ nutritional supplement SKUs
Slide 10: Personalization Drives Scientific Wellness
Personalization Drives Scientific Wellness Demographics Purchase history Health profile ThorneHealthTech Recommendation Inputs Molecular portrait Content interactions Diet Activity Supplement Content Thorne HealthTech
Slide 11: Thorne HealthTech at a Glance
Thorne HealthTech at a Glance Thorne HealthTech $138.5MM in 2020, up 35% over 2019 $135.4MM Q1-Q3 2021(2) Revenue $15.3MM in 2020, up 88% over 2019 $15.1MM Q1-Q3 2021(2) Adjusted EBITDA(1) 7.6x LTV / CAC Ratio for direct-to-consumer (DTC) customers in 2020 Marketing / Brand Highlights 70 NPS 2
Slide 12: Fundamental Business Attributes
Fundamental Business Attributes Thorne HealthTech
Slide 13: Investment Highlights
Investment Highlights Large, growing addressable market with powerful tailwinds Thorne has created a trusted, luxury brand Redefining consumer health and wellness Scalable business model / Differentiated channel strategy Integrated business model across entire value chain Experienced, science-driven
Slide 14: Large, Growing Addressable Markets with Powerful Tailwinds
Thorne HealthTech Large, Growing Addressable Markets with Powerful Tailwinds https://www.marketsandmarkets.com/Market-Reports/point-of-care-diagnostic-market-106829185.html; $29.5B in 2020. 11.4% projected CAGR from 2020-2025. https://www.bccresearch.com/market-research/biotechnology/drug-discovery-
Slide 15: Scalable Business Model / Differentiated Channel Strategy
Consumers Professional/B2B Customer: Thorne DTC Amazon DTC Health Professionals, Hospitals, Athletes, International, B2B Business Model: E-Commerce Subscriptions (34%)1 E-Commerce / Sales Force / Distributors / Biz Dev Go-to-market Strategy: Amazon, Thorne.com Sales Force, Thorne.com, Performance Pa
Slide 16: Integrated Business Model Across Entire Value Chain
Thorne HealthTech Integrated Business Model Across Entire Value Chain 23 scientists and engineers AI-driven analytics of multi-omic database New compounds / products / Indications Data-driven R&D Manufacturing Distribution / E-commerce Customer engagement / brand marketing Data analytics / Health an
Slide 17: Experienced, Science-Driven Team with Proven Track Record
Paul JacobsonCo-founder, Chief Executive Officer11 years @ Thorne HealthTech Tom McKennaChief Operating Officer11 years Scott HurthChief Technology Officer7 years Scott WheelerChief Financial Officer10 years Michelle CrowChief Marketing Officer9 years Nathan Price, Ph.D.Chief Executive Offic
Slide 18: Growth Drivers and Initiatives
Growth Drivers and Initiatives Thorne HealthTech
Slide 19: Overview of Key Growth Initiatives and Opportunities
Overview of Key Growth Initiatives and Opportunities Increase Brand Awareness Expand Strategic and Cross Industry Relationships New Products / Innovations Further Expand into International Markets Thorne HealthTech Selectively Pursue Acquisitions
Slide 20: Increase Brand Awareness to Capitalize on Growing Demand
Increase Brand Awareness to Capitalize on Growing Demand for Scientific Wellness Thorne HealthTech Increase marketing spend Historical spend under 10% of sales Up to 14.8% for Q1-Q3 2021 Brand campaign has historically increased daily sales by 25% Onboard new partners and influencers Mayo Clinic, US
Slide 21: Clinical Research Studies Support Brand and Partnerships
Clinical Research Studies Support Brand and Partnerships Thorne HealthTech Clinical research enables us to: Validate the safety and efficacy of new ingredients Expand the indications of existing products Develop novel testing systems for new health conditions Ongoing trials Clinical research drives
Slide 22: Expand Strategic and Cross Industry Relationships
Expand Strategic and Cross Industry Relationships 100+ Sports Teams 1000s Pro Athletes Performance Sponsorships Onegevity Research Engagements and Collaborations Thorne HealthTech 11 U.S. Olympic Teams
Slide 23: Evidence Based Product Innovation
Evidence Based Product Innovation Thorne HealthTech Big Data Mining Microbiome Analysis Analysis of Sample Collection Attributes Rationale Onegevity Input Thorne Output Timing Biological Age Biomarkers Biological Age Test and recommendations Advanced Nutrients w/ NR Gut Health Test Prebiotic+ Querce
Slide 24: Thorne Biological Age & Gut Health Tests
Thorne Biological Age & Gut Health Tests LipidAge 50 ChronologicalAge 49 Global Age 50 ChronologicalAge 45 ImmuneAge 50 ChronologicalAge 46 Metabolic Age 50 ChronologicalAge 48 Science-backed Clinically-validated correlations with disease risksHealth program shows ability to lower biological age Tho
Slide 25: Next Generation Microbiome Wipe to Improve Customer Experience
Next Generation Microbiome Wipe to Improve Customer Experience Global patent application pending Aim to launch in Q1 2022
Slide 26: Long-Term Growth Targets
Long-Term Growth Targets(1) Thorne HealthTech These are not projections; they are long-term growth targets, are forward-looking, are subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the company and its management and
Slide 27: Why Thorne HealthTech Can Transform Human Health
Thorne HealthTech Why Thorne HealthTech Can Transform Human Health . Supplements aren't created equal: The quality of our products, controlled through our US-supply chain, is recognized by industry leaders and influencers as among the best. Patients are demanding preventive solutions, not just sick-
Slide 28: Thank You
Thank You Thome HealthTech 28
Slide 29: Appendix
Appendix Thorne HealthTech
Slide 30: Key Financial Highlights
Key Financial Highlights Thorne HealthTech Sales composition Gross margin overview EBITDA margin overview
Slide 31: Sales Composition by Channel Over Time
Sales Composition by Channel Over Time Thorne HealthTech COMPOSITION OF SALES BY CHANNEL ($MM) Professional/B2B DTC 35% Total Growth 32% Total Growth
Slide 32: Healthy Gross Margins with Room to Expand
Thorne HealthTech Gross Margin (%) Healthy Gross Margins with Room to Expand Gross margins continue to improve due to operational improvement and higher average sales price 2018 - 2019 plant startup and associated inefficiencies 2020 - 2021 productivity gains and fixed cost leverage Gross Profit ($M
Slide 33: Strong Adjusted EBITDA Margins
Thorne HealthTech Adj. EBITDA ($MM) Strong Adjusted EBITDA Margins(1) Adjusted EBITDA amounts and margins increased because of: Strong sales growth Gross margin improvements from cost leverage and operating efficiencies, such as fewer changeovers from longer production runs Significant operating lev
Slide 34: EBITDA and Adj. EBITDA Calculation
EBITDA and Adj. EBITDA Calculation Thorne HealthTech
Thorne HealthTech — Investor Presentation (December 2021) on 6ix